RxSight, Inc.
RXST Nasdaq· Ophthalmic Goods
Last close · Oct 27, 2026
$4.90
KIRA · Stoqly’s AI analyst, in plain words
- RxSight, Inc. had $134M of revenue in fiscal 2025, down 3.9% on the year before. Over five years, revenue changed +55.7% a year on average.
- Its operating margin was −35.8%, down 9.5 pts: of every 100 in sales, about −36 is left after running the business.
- RxSight, Inc. lost $38.9M in fiscal 2025.
- Free cash flow was −$19.3M in fiscal 2025, −14.4% of revenue.
Market cap
$203M
P/E
—
Revenue
$134M
Net income
−$38.9M
Free cash flow
−$19.3M
Operating margin
−35.8%
RxSight, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−3.9%
No. Sales fell 3.9% last year.
Does it make a profit?
−29.0%
No. It lost money last year.
Does profit turn into cash?
−14.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What RxSight, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- RxSight, Inc.
- CIK
- 0001111485
RxSight, Inc. · RXST
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $22.6M | $49.0M | $89.1M | $140M | $134M |
| Revenue growth | 53.9% | 116.9% | 81.8% | 57.1% | −3.9% |
| Gross margin | 20.0% | 43.5% | 60.4% | 70.7% | 76.6% |
| Operating margin | −233.6% | −129.2% | −56.2% | −26.3% | −35.8% |
| Net income | −$48.7M | −$66.8M | −$48.6M | −$27.5M | −$38.9M |
| Net margin | −215.5% | −136.2% | −54.6% | −19.6% | −29.0% |
| Diluted EPS | −$3.57 | −$2.41 | −$1.41 | −$0.71 | −$0.95 |
| Cash | |||||
| Cash from operations | −$44.7M | −$58.9M | −$41.6M | −$16.9M | −$15.5M |
| Capital expenditure | $1.9M | $2.4M | $4.8M | $5.4M | $3.8M |
| Free cash flow | −$46.6M | −$61.2M | −$46.4M | −$22.4M | −$19.3M |
| FCF margin | −206.5% | −125.0% | −52.1% | −16.0% | −14.4% |
| Share count change | 146.3% | 103.0% | 24.6% | 12.8% | 5.1% |
| Debt and strength | |||||
| Cash and short-term investments | $159M | $106M | $127M | $237M | $228M |
| Debt incl. finance leases | $39.8M | $40.4M | $0.2M | — | — |
| Shareholders' equity | $138M | $89.9M | $160M | $281M | $276M |
| Current ratio | 15.9x | 7.8x | 8.1x | 11.4x | 10.9x |
| Interest coverage | −14.3x | −12.8x | −15.1x | −1,755.1x | −2,536.4x |
| Returns and quality | |||||
| Return on capital | −223.4% | −206.1% | −119.3% | — | — |
| Return on equity | — | −58.5% | −38.8% | −12.4% | −14.0% |
| Return on tangible equity | −35.2% | −74.3% | −30.3% | −9.8% | −14.1% |
| Piotroski F-score | 4 | 3 | 6 | 4 | 2 |
| Altman Z'' | −1.7 | −8.0 | 0.4 | 6.3 | 5.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
4 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
RxSight, Inc. · RXST
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.90 a share, the company is worth $203M.
Source: SEC EDGAR XBRL filings (CIK 0001111485). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.